Bevacizumab as a treatment option for radiation-induced cerebral necrosis

Strahlentherapie und Onkologie

Volumn 187, Issue 2, 2011, Pages 135-139

  Matuschek, Christiane ^a   Bölke, Edwin ^a   Nawatny, Jens ^b   Hoffmann, Thomas K ^c   Peiper, Matthias ^d   Orth, Klaus ^d   Gerber, Peter Arne ^b   Rusnak, Ethelyn ^e   Lammering, Guido ^a,f   Budach, Wilfried ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

^d Catholic Hospital Essen   (Germany)

^e UNIVERSITY AT BUFFALO   (United States)

^f MAASTRO CLINIC   (Netherlands)

Author keywords

Bevacizumab; Cerebral radiation necrosis; Hypoxia; Radiation therapy; Stereotactic neurosurgery

Indexed keywords

ANTIBIOTIC AGENT; BEVACIZUMAB; DEXAMETHASONE; TEMOZOLOMIDE; ALKYLATING AGENT; ANGIOGENESIS INHIBITOR; DACARBAZINE; DRUG DERIVATIVE; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

ADULT; ARTICLE; ASTROCYTOMA; BRAIN NECROSIS; CANCER RADIOTHERAPY; CANCER RELAPSE; CASE REPORT; COGNITION; CONTRAST ENHANCEMENT; DRUG WITHDRAWAL; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; MALE; NEUROIMAGING; PNEUMONIA; POSITRON EMISSION TOMOGRAPHY; RADIATION DOSE DISTRIBUTION; RADIATION NECROSIS; SEPSIS; STEREOTACTIC RADIOSURGERY; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BLOOD BRAIN BARRIER; BRAIN; BRAIN EDEMA; BRAIN TUMOR; COMPUTER ASSISTED RADIOTHERAPY; DRUG ANTAGONISM; DRUG EFFECT; MULTIMODALITY CANCER THERAPY; NECROSIS; NEUROLOGIC EXAMINATION; PATHOLOGY; RADIATION DOSE; RADIATION EXPOSURE; RADIATION INJURY; RADIOSURGERY; REVIEW; TUMOR RECURRENCE;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, ALKYLATING; ASTROCYTOMA; BLOOD-BRAIN BARRIER; BRAIN; BRAIN EDEMA; BRAIN NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DACARBAZINE; HUMANS; MALE; NECROSIS; NEOPLASM RECURRENCE, LOCAL; NEUROLOGIC EXAMINATION; RADIATION INJURIES; RADIOSURGERY; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, ADJUVANT; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 79954428113     PISSN: 01797158     EISSN: 1439099X     Source Type: Journal    
DOI: 10.1007/s00066-010-2184-4     Document Type: Article

References (25)

1. Andisheh B, Brahme A, Bitaraf MA, et al. Clinical and radiobiological advantages of single-dose stereotactic light-ion radiation therapy for large intracranial arteriovenous malformations. Technical note. J Neurosurg 2009;111:919-26.
2. Azzam EI, Yang Z, Li M, et al. The effect of human cord blood therapy on the intestinal tract of lethally irradiated mice: possible use for mass casualties. Int J Radiat Biol;86:467-75.
3. Castinetti F, Brue T. [Radiotherapy and radiosurgery of pituitary adenomas]. Presse Med 2009;38:133-9.
4. Cheung MC, Chan AS, Law SC, et al. Impact of radionecrosis on cognitive dysfunction in patients after radiotherapy for nasopharyngeal carcinoma. Cancer 2003;97:2019-26. (Pubitemid 36397281)
5. Fokas E, Wacker U, Gross MW, et al. Hypofractionated stereotactic reirradiation of recurrent glioblastomas: a beneficial treatment option after high-dose radiotherapy? Strahlenther Onkol 2009;185:235-40.
6. Gonzalez J, Kumar AJ, Conrad CA, et al. Effect of bevacizumab on radiation necrosis of the brain. Int J Radiat Oncol Biol Phys 2007;67:323-6. (Pubitemid 46108339)
7. Gutin PH, Iwamoto FM, Beal K, et al. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 2009;75:156-63.
8. Henke G, Paulsen F, Steinbach JP, et al. Hypofractionated reirradiation for recurrent malignant glioma. Strahlenther Onkol 2009;185:113-9.
9. Henzel M, Hamm K, Sitter H, et al. Comparison of stereotactic radiosurgery and fractionated stereotactic radiotherapy of acoustic neurinomas according to 3-D tumor volume shrinkage and quality of life. Strahlenther Onkol 2009;185:567-73.
10. Hyakkoku K, Nakajima Y, Izuta H, et al. Thalidomide protects against ischemic neuronal damage induced by focal cerebral ischemia in mice. Neuroscience 2009;159:760-9.
11. Kang KB, Wang TT, Woon CT, et al. Enhancement of glioblastoma radioresponse by a selective COX-2 inhibitor celecoxib: inhibition of tumor angiogenesis with extensive tumor necrosis. Int J Radiat Oncol Biol Phys 2007;67:888-96. (Pubitemid 46215892)
12. Levin VA, Bidaut L, Hou P, et al. Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys 2010 Apr 15 [Epub ahead of print].
13. Liu AK, Macy ME, Foreman NK. Bevacizumab as therapy for radiation necrosis in four children with pontine gliomas. Int J Radiat Oncol Biol Phys 2009;75:1148-54.
14. Marks JE, Wong J. The risk of cerebral radionecrosis in relation to dose, time and fractionation. A follow-up study. Prog Exp Tumor Res 1985;29:210-218.
15. Mizumoto M, Nakayama H, Tokita M, et al. Technical considerations for noncoplanar proton-beam therapy of patients with tumors proximal to the optic nerve. Strahlenther Onkol 2010;186:36-9.
16. Nikitin KV, Shishkina LV, Pronin IN, et al. [Radiation necrosis after stereo- tactic radiosurgery for benign glioma]. Zh Vopr Neirokhir Im N N Burdenko 2009:37-42; discussion 42.
17. Prasanna PG, Uma Devi P. Modification of WR-2721 radiation protection from gastrointestinal injury and death in mice by 2-mercaptopropionylglycine. Radiat Res 1993;133:111-5. (Pubitemid 23070034)
18. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009;27:1227-34.
19. Sterzing F, Welzel T, Sroka-Perez G, et al. Reirradiation of multiple brain metastases with helical tomotherapy. A multifocal simultaneous integrated boost for eight or more lesions. Strahlenther Onkol 2009;185:89-93.
20. Torcuator R, Zuniga R, Loutfi R, et al. Bevacizumab and irinotecan treatment for progressive diffuse brainstem glioma: case report. J Neurooncol 2009;93:409-12.
21. Torcuator R, Zuniga R, Mohan YS, et al. Initial experience with bevacizumab treatment for biopsy confirmed cerebral radiation necrosis. J Neurooncol 2009;94:63-8.
22. Tsao MN, Li YQ, Lu G, et al. Upregulation of vascular endothelial growth factor is associated with radiation-induced blood-spinal cord barrier breakdown. J Neuropathol Exp Neurol 1999;58:1051-60. (Pubitemid 29468266)
23. Williams KJ, Telfer BA, Shannon AM, et al. Inhibition of vascular endothelial growth factor signalling using cediranib (RECENTIN; AZD2171) enhances radiation response and causes substantial physiological changes in lung tumour xenografts. Br J Radiol 2008;81 Spec No 1:S21-7.
24. Wilson CM, Gaber MW, Sabek OM, et al. Radiation-induced astrogliosis and blood-brain barrier damage can be abrogated using anti-TNF treatment. Int J Radiat Oncol Biol Phys 2009;74:934-41.
25. Wong ET, Huberman M, Lu XQ, et al. Bevacizumab reverses cerebral radiation necrosis. J Clin Oncol 2008;26:5649-50.